Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA
about
Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issuesRole of elosulfase alfa in mucopolysaccharidosis IVAMorquio A syndrome: diagnosis and current and future therapiesBurden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey.Orthopedic management of the extremities in patients with Morquio A syndrome.Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.Therapies of mucopolysaccharidosis IVA (Morquio A syndrome).Mortality in patients with morquio syndrome a.Overcoming the barriers to diagnosis of Morquio A syndromeImpact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.MRI morphometric characterisation of the paediatric cervical spine and spinal cord in children with MPS IVA (Morquio-Brailsford syndrome).Diagnosing mucopolysaccharidosis IVAEnzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations.Review of clinical presentation and diagnosis of mucopolysaccharidosis IVAImpact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA.Current therapies for Morquio A syndrome and their clinical outcomes.Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management.Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase Alfa.Home infusion with Elosulfase alpha (VimizimR) in a UK Paediatric setting.Neurophysiology of hearing in patients with mucopolysaccharidosis type IV.International guidelines for the management and treatment of Morquio A syndrome.Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study.Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.
P2860
Q26738901-F6072F2D-76D6-4116-B808-66F3FAF657F2Q26745750-1A55B980-3BFE-4399-AA12-C5087524FAB8Q27014063-11EEF59C-7641-4087-8FB7-3D2D12652277Q33590912-1CA8F26C-24C6-41A4-BC44-C531A4669719Q34028791-F4743D0B-32EA-41A4-9370-4BA0DACBFBC4Q34389992-0062924F-ED79-4933-813B-FEA1B6313650Q34545883-73C572BD-82FE-48D5-80D0-D39323A12571Q34734640-D20F695D-D613-4DE4-91B0-618DE51A49CEQ34789123-D5D6ABC3-4A64-4982-B292-D29B9026177CQ35319254-BC5C6C06-A811-4BB3-9265-C8024D443E21Q36426886-A076DA49-AE97-4416-A5CF-D0508446877EQ36662839-D2C422D5-87B5-4145-A3BC-9A8D27A5DCC8Q36662855-2E812C4E-A7F9-4864-A086-20F181FCFE01Q36677856-1221DBC4-45B2-444B-BC6A-B7EA502F48BAQ37126295-3D8C1C53-3055-4552-8D90-3CACAB9C3649Q37341874-C8A3B1EF-A7AD-46D8-97D1-26B393C74F2CQ37585553-87BE5FE2-F875-4A6C-B8FD-AFFDE376BD58Q37646091-F7838665-8C98-46ED-938C-11F5F6E2EC02Q38079402-0BE27D48-5CE5-40B8-AA5B-C709C954C424Q38246994-FAFEE872-9AC4-437A-B094-D0730C8D7889Q38794433-F22EAE79-97CB-406C-A807-90D8A5DFB1E7Q49847145-FD0424BB-8F12-47E2-B682-1D7CD5D8BDF1Q49850720-0A3D87E4-C077-491B-B3D5-13C2F0269A19Q50300965-A57C85A8-44CD-491E-81A1-74B3CDD0F1B9Q53082504-5742783F-A94F-456C-9A23-0E76F5F6455BQ54191084-18D3CBA2-AD0C-4330-883F-7EB88B476AE0Q54251569-6D481490-D51C-4233-9239-310EF5477427
P2860
Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical overview and treatmen ...... mucopolysaccharidosis type IVA
@ast
Clinical overview and treatmen ...... mucopolysaccharidosis type IVA
@en
type
label
Clinical overview and treatmen ...... mucopolysaccharidosis type IVA
@ast
Clinical overview and treatmen ...... mucopolysaccharidosis type IVA
@en
prefLabel
Clinical overview and treatmen ...... mucopolysaccharidosis type IVA
@ast
Clinical overview and treatmen ...... mucopolysaccharidosis type IVA
@en
P2093
P2860
P50
P1476
Clinical overview and treatmen ...... mucopolysaccharidosis type IVA
@en
P2093
C Gail Summers
Ciarán Mc Ardle
Elizabeth Braunlin
Elizabeth Wright
Rebecca Lawrence
Sara M Hawley
P2860
P2888
P304
P356
10.1007/S10545-012-9459-0
P577
2012-02-23T00:00:00Z
P5875
P6179
1050817198